Keros Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Keros Therapeutics Inc 's ROA in the second quarter of 2026?
Keros Therapeutics Inc recorded a cumulative net loss of $-83 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -19.79%.

However, within the Healthcare sector 357 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 486 to 3367.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-60.94 %	-60.17 %	-45.05 %	28.26 %	62.43 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-83	-85	87	64	19
Return On Assets (TTM)	-19.79 %	-15.98 %	13.37 %	8.95 %	2.76 %
KROS's Total Ranking	# 3367	# 486	# 690	# 1638	# 2334
Total Assets (TTM) in million	289	312	338	742	739
Seq. Total Assets Change	-7.57 %	-7.61 %	-54.44 %	0.38 %	-5.73 %
Seq. Net Income Change	-	-	-	-	-

KROS's 5 Years Annual ROA >> Back to KROS Management Effectiveness >> Compare KROS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 130
Sector	# 358
Overall	# 3416

Return On Assets Statistics
High	Average	Low
13.27 %	-25.64 %	-42.59 %
(Dec 31 2025)		(Dec 31 2023)

News about Keros Therapeutics Inc Return on Assets ROA

Advances in TGF-β Modulation Keros Therapeutics Path Forward in Pulmonary Arterial Hypertension, Myelodysplastic Sy...

In recent months, Keros Therapeutics, Inc. has made significant strides in its clinical research endeavors, focusing on the modulation of the transforming growth factor-beta (TGF-β) signaling pathway. This pathway has been implicated in a variety of disorders, and Keros has targeted its therapeutic development towards conditions such as pulmonary arterial hypertension (PAH), myelodysplastic syndromes (MDS), and obesity.On September 3, 2024, Keros announced the closure of screening for the Phase 2 TROPOS trial, which evaluates the efficacy of cibotercept (KER-012) in combination with standard background therapy for patients diagnosed with PAH. The trial has progressed to a stage where Keros anticipates completing enrollment by the end of September 2024, with an expected presentation of topline results in the second quarter of 2025. The TROPOS trial represents a critical advancement in the field of PAH treatment, aiming to address a condition characterized by elevated blood pressure in the pulmonary arteries, leading to significant morbidity and mortality.

Financial Statements
Keros Therapeutics Inc 's Assets	$ 289 million	KROS's Balance sheet
Keros Therapeutics Inc 's Income	$ -29 million	Quarterly KROS's Income Statement
KROS's Income by Division		See KROS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-45.05 %	66.51 %	20.81 %	20.02 %	-5.44 %
Total Assets in million	338	615	369	306	255
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	87	-187	-153	-105	-59
Annual Return On Assets	25.74 %	-30.46 %	-41.41 %	-34.23 %	-23.06 %

KROS's 5 Years Annual ROA >> Back to KROS Management Effectiveness >> Compare KROS ROA to its Competitors

Comment on KROS's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 25.74 % compared to prior year, due to annual net income growth of % to $87.01 million, and due to decline of value in Keros Therapeutics Inc 's assets by -45.05 % to $338.02 million, compared to $338.02 a year before.

More Return On Assets Ratios
KROS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KROS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KROS's Competitors
Subscribers only: Roa for Keros Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for KROS's Customers

You may also want to know
KROS's Roi	KROS's Inventory Turnover Ratio	KROS's Growth Rates	KROS's Dividend Comparisons
	KROS's Profitability Ratios	KROS's Asset Turnover Ratio	KROS's Dividend Growth
KROS's Roe	KROS's Valuation Ratios	KROS's Financial Strength Ratios	KROS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T18:37:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.